OCUL Ocular Therapeutix Inc.

5.69
-0.06  -1%
Previous Close 5.75
Open 5.74
Price To book 3.45
Market Cap 165334165
Shares 29,056,971
Volume 219,768
Short Ratio 16.74
Av. Daily Volume 292,652

SEC filingsSee all SEC filings

  1. 8-K - Current report 171138833
  2. 8-K - Current report 171136915
  3. 8-K - Current report 171098671
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015078
  5. 8-K - Current report 171014856

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released November 14, 2016. Primary endpoints met.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial to be initiated pending data from a non-significant risk device study to be initiated in 2017.
DEXTENZA
Allergic conjunctivitis
Phase 3 initiated October 2016. Data due 1H 2018.
OTX-TP
Glaucoma and ocular hypertension
CRL July 25 2016 - due to manufacturing deficiencies. NDA resubmitted, PDUFA date July 19, 2017. Further CRL issued July 11, 2017 with FDA noting deficiencies in manufacturing processes and analytical testing.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease

Latest News

  1. How Does Investing In Ocular Therapeutix Inc (OCUL) Impact Your Portfolio?
  2. Robbins Arroyo LLP Is Investigating the Officers and Directors of Ocular Therapeutix, Inc. (OCUL) on Behalf of Shareholders
  3. Ocular Therapeutix™ Appoints Donald Notman as Chief Financial Officer
  4. Have Investors Already Priced In Ocular Therapeutix Inc’s (OCUL) Growth?
  5. Ocular Therapeutix™ Appoints Michael Goldstein, M.D., M.B.A., as Chief Medical Officer
  6. Ocular Therapeutix™ to Present at Three Upcoming Investor Conferences
  7. OCUL DEADLINE TODAY: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017
  8. FINAL DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
  9. SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocular Therapeutix, Inc. of Class Action Lawsuit and Upcoming Deadline - OCUL
  10. DEADLINE TUESDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
  11. DEADLINE TUESDAY: The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf of Ocular Therapeutix, Inc. Shareholders and a Lead Plaintiff Deadline of September 5, 2017 (OCUL)
  12. 5-DAY DEADLINE: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
  13. DEADLINE ALERT:  Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Ocular Therapeutix, Inc. (Nasdaq:OCUL) To Contact The Firm
  14. EQUITY ALERT UPDATE: Rosen Law Firm Announces Filing of Securities Class Action Against Ocular Therapeutix, Inc. - OCUL
  15. UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders It Filed a Class Action Complaint on Behalf of Ocular Therapeutix, Inc. Shareholders and Lead Plaintiff Deadline is Set for September 5, 2017 - OCUL
  16. DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Ocular Therapeutix, Inc. (OCUL) and Lead Plaintiff Deadline: September 5, 2017
  17. SEPTEMBER 5 DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Ocular Therapeutix, Inc. and Encourages Investors with Losses to Contact the Firm
  18. OCUL EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Ocular Therapeutix, Inc. and a Lead Plaintiff Deadline of September 5, 2017

SEC Filings

  1. 8-K - Current report 171138833
  2. 8-K - Current report 171136915
  3. 8-K - Current report 171098671
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015078
  5. 8-K - Current report 171014856
  6. 8-K - Current report 171005344
  7. 8-K - Current report 17996965
  8. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17957714
  9. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17957105
  10. 8-K - Current report 17925464